Metronomic chemo plus nivolumab (TMC-I) improves survival in R/M head & neck cancer vs platinum chemotherapy

Early ctDNA clearance linked to improved outcomes in KRAS G12C-mutant colorectal cancer

Giredestrant plus palbociclib shows limited benefit in ER-positive, HER2-negative metastatic breast cancer

Concurrent thoracic radiotherapy plus chemo-ICI shows no overall survival benefit in ES-SCLC

Amivantamab plus pembrolizumab and carboplatin in R/M HNSCC: Evaluating improved response and survival vs chemo

Talazoparib plus enzalutamide improves radiographic progression-free survival in HRR-altered mCSPC

Sacituzumab govitecan improves PFS across Trop-2, BRCA, and HER2 metastatic triple-negative breast cancer

Sacituzumab govitecan plus pembrolizumab improves PFS across biomarker subgroups in metastatic triple-negative breast cancer

2: Managing EGFR inhibitor side effects in NSCLC - Skin toxicity impact, adherence challenges, and nursing management

3: MDT collaboration in NSCLC - Aligning oncologists, nurses, and patients to enhance EGFR inhibitor treatment pathways and supportive care

Personalised mRNA vaccine plus pembrolizumab shows durable benefit in high-risk melanoma

ASCO 2026: Highlights and analysis